JMP Securities analyst Constantine Davides lowered the firm’s price target on Evolent Health (EVH) to $12 from $18 and keeps an Outperform rating on the shares amid a broader research note on Healthcare Services. The firm lowered its 2025 and 2026 EBITDA estimates to $161M and $185M, respectively from $215M and $250M, due to recently disclosed revenue and profit headwinds and tailwinds that will impact the company’s financials in 2025, the analyst says.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $16 from $23 at Canaccord
- Evolent Health price target lowered to $15 from $20 at Truist
- Evolent Health price target lowered to $20 from $29 at BTIG
- Evolent Health price target lowered to $12 from $16 at Stephens
- Evolent Health price target lowered to $14 from $27 at UBS